fbpx

PRESS RELEASE

OTTAWA, April 12th, 2021

OTTAWA, ONTARIO —Vaultt and Boehringer Ingelheim (Canada) Ltd. today announced that  they’ve entered into a partnership to develop a new integrated functionality on the Vaultt  mobile app that will allow users to create a Portable Document Format (PDF) Medical Care  Passport with their healthcare information stored within Vaultt. Vaultt is an all-in-one caregiver  management tool that empowers patients, families and caregivers by helping them organize,  store and share important information easily and securely. Patients will now have the ability to  maintain and update their health information in a Medical Care Passport. This document can be  shared instantly by fax or email with the appropriate hospital department and includes  important patient information, providing healthcare teams with an accurate patient medical  history.  

This partnership will focus on improving the health journey for patients with chronic conditions  such as those with rare lung diseases. Interstitial lung diseases (ILDs) encompass more than 200  disorders that can lead to irreversible scarring of lung tissue, negatively impacting lung  function.i 

The COVID-19 pandemic has shown many ILD patients, such as those with Progressive Fibrosing  ILD (PF-ILD) and Idiopathic Pulmonary Fibrosis (IPF), are at an increased risk due to fragmented  patient electronic records. This leads to healthcare providers not having access to a complete  patient medical record when they need it. The collaboration between Boehringer-Ingelheim  Canada and Vaultt aims to solve this problem by making it easier for caregivers and patients to  store and share medical information such as current medical conditions, healthcare providers  and contact information, diagnostics,medication list, pharmacy information, personal directive  and palliative care, and goals of care designation.  

“We hope this partnership with Boehringer Ingelheim Canada will help patients during their  time of need get the level of care they deserve,” says Audrey Bond, Chief Executive Officer of  Vaultt. “No patient should be at risk of inadequate care due to the fragmentation of medical  records. We’re here to remove the burden on caregivers, patients, and healthcare providers by  simplifying the care and medical record sharing process using our secure patient-centric  solution.”  

“At Boehringer Ingelheim Canada, we believe innovative technologies can offer better  healthcare for IPF/PF-ILD patients,” says Annie Beauchemin, Executive Director Patient Access,  Health Economics & Outcomes Research, HealthCare Solutions. “These patients are at an  increased risk of an emergency due to COVID-19 from pre-existing respiratory symptoms.  Enabling patients and their caregivers’ quick access to personal and up to date health  information is important to ensure the best health outcome.” 

This feature is expected to roll out in April 2021 will be available to all Vaultt users. To learn  more, visit Vaultt.com or download the Vaultt App. 


About Vaultt
 

Vaultt is an Ottawa based tech startup that empowers patients, families and caregivers by  helping them organize, store and share important information easily and securely. Vaultt’s  easy-to-use mobile app helps to build a more complete picture of a patient’s health and  enables real-time and on-demand access to critical information, documentation, schedules,  calendars and tasks that can be shared between family members, caregivers and trusted  professionals. Built in Canada, Vaultt is secure by design with true end-to-end encryption to  protect users’ sensitive personal data. Partnering with healthcare providers, Vaultt enables  patients and families to proactively manage their health through the secure storage and sharing  of vital care information, ultimately improving patient care and outcomes. For more  information, please visit https://www.vaultt.com/ 


About Boehringer Ingelheim (Canada) Ltd. 

Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and  animals. As a leading research-driven biopharmaceutical company, the company creates value  through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever  since, Boehringer Ingelheim takes a long-term perspective. Approximately 52,000 employees serve  more than 130 markets in the three business areas, Human Pharma, Animal Health and  Biopharmaceutical Contract Manufacturing. The Canadian headquarters of Boehringer Ingelheim  was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer  Ingelheim employs approximately 600 people across Canada. Learn more at www.boehringer ingelheim.ca. 

Media Contact:

Audrey Bond
audrey@vaultt.com
(613) 894-5834

i British Lung Foundation. What is pulmonary fibrosis? Available at: https://www.blf.org.uk/support-for-you/pulmonary-fibrosis/what-is pulmonary-fibrosis [Accessed April 2021].